Monthly Horizon Scanning Report – February 2023

Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licenses, significant new guidance, and decisions that have been made by recognised bodies. 

This information is produced for use by NHS healthcare professionals. 

Prescribing Update Newsletter – February 2023

Prescribing support newsletters aim to inform readers of work done by the unit and work in progress, to help tailor local work plans and highlight any ‘topical’ issues in prescribing or medicines management.

If you have any suggestions for future topics for the newsletter, then please contact nuth.nyrdtc.rxsupp@nhs.net

This month’s edition focuses on RDTC resources to help you make the most of your budget, updates to the cost comparison charts, the voluntary recall of certain FreeStyle Libre 2 sensors, and an E-learning programme on internet safety, suicide, and self-harm. It highlights recent publications from the RDTC including a series of publications as part of the Polypharmacy and Overprescribing theme reviewing opioid prescribing, and a Prescribing Bulletin looking at the budget impact of Metformin immediate release 1g tablets. It also includes another in the series of “Meet the Team” where you can get to know the people behind the work we do. There is also information on some key medicines availability issues and serious shortage protocols

Polypharmacy & Overprescribing: Opioid population health management

Prescribing for Population Health (PPH) is an ongoing series that aims to support ICSs to improve the health of the populations they serve. PPHs use prescribing data, biomedical literature and other data sources to provide new insights.

In recent years, there has been increasing concern regarding the overprescribing of opioids and associated harms. The RDTC has produced a series of publications as part of the Polypharmacy and Overprescribing theme reviewing opioid prescribing:

Each publication includes considerations and interventions for medicines optimisation teams and health systems. To avoid duplication across this series of overprescribing and polypharmacy opioid publications, the suggested actions have only been listed in the most relevant theme but may apply across all. We recommend reading all parts of the series sequentially to ensure the breadth of potential actions are known.

This is the third part of the series which focuses on the population health management of patients prescribed opioids, specifically in terms of deprivation level and the impact on sustainability and climate change.

Use the following links to access the first part in the series entitled ‘Opioid patient populations’ and the second in the series entitled ‘Opioid patient demographics’

This publication is part of our Strategic Support and Planning contract. To gain access please email us at nuth.nyrdtc.rxsupp@nhs.net.   

Polypharmacy & Overprescribing: Opioid patient demographics

Prescribing for Population Health (PPH) is an ongoing series that aims to support ICSs to improve the health of the populations they serve. PPHs use prescribing data, biomedical literature and other data sources to provide new insights.

In recent years, there has been increasing concern regarding the overprescribing of opioids and associated harms. The RDTC has produced a series of publications as part of the Polypharmacy and Overprescribing theme reviewing opioid prescribing:

Each publication includes considerations and interventions for medicines optimisation teams and health systems. To avoid duplication across this series of overprescribing and polypharmacy opioid publications, the suggested actions have only been listed in the most relevant theme but may apply across all. We recommend reading all parts of the series sequentially to ensure the breadth of potential actions are known.

This is the second part of the series which focuses on the demographics of the patient populations prescribed opioids.

Use the following link to access the first part in the series entitled ‘Opioid patient populations

This publication is part of our Strategic Support and Planning contract. To gain access please email us at nuth.nyrdtc.rxsupp@nhs.net.   

Polypharmacy & Overprescribing: Opioid patient populations

Prescribing for Population Health (PPH) is an ongoing series that aims to support ICSs to improve the health of the populations they serve. PPHs use prescribing data, biomedical literature and other data sources to provide new insights.

In recent years, there has been increasing concern regarding the overprescribing of opioids and associated harms. The RDTC has produced a series of publications as part of the Polypharmacy and Overprescribing theme reviewing opioid prescribing:

Each publication includes considerations and interventions for medicines optimisation teams and health systems. To avoid duplication across this series of overprescribing and polypharmacy opioid publications, the suggested actions have only been listed in the most relevant theme but may apply across all. We recommend reading all parts of the series sequentially to ensure the breadth of potential actions are known.

In this first part of the series, the focus is on the patient populations prescribed opioids and the inter-relationships and dependencies between prescribing and the available metrics.

This publication is part of our Strategic Support and Planning contract. To gain access please email us at nuth.nyrdtc.rxsupp@nhs.net.   

Pain Management

Overview

This report looks at prescribing trends in primary care in relation to Pain Management at ICB and Sub Integrated Board location (SICBl) with particular focus on Opioid and Non-opioid analgesics, Neuropathic pain, Antimigraine drugs and Osteoarthritis.

If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net

Frequency

Bi-annually

Data Period

October 2020 to September 2023

Monthly Horizon Scanning Report – January 2023

Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licenses, significant new guidance, and decisions that have been made by recognised bodies. 

This information is produced for use by NHS healthcare professionals. 

Formulary assessment – Morphine sulfate (Actimorph) orodispersible tablets

Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.

The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.

This information is produced for use by NHS healthcare professionals and RDTC stakeholders.

Prescribing Update Newsletter – December 2022

Prescribing support newsletters aim to inform readers of work done by the unit and work in progress, to help tailor local work plans and highlight any ‘topical’ issues in prescribing or medicines management.

If you have any suggestions for future topics for the newsletter, then please contact nuth.nyrdtc.rxsupp@nhs.net

This month’s edition focuses on polypharmacy, influenza in the community – prescribing antivirals, group A streptococcus in children – advice for clinicians, and the MHRA review on the safe use of valproate. We also include recent publications from the RDTC and another in the series of “Meet the Team” where you can get to know the people behind the work we do. There is also information on some key medicines availability issues and serious shortage protocols.

Monthly Horizon Scanning Report – December 2022

Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licenses, significant new guidance, and decisions that have been made by recognised bodies. 

This information is produced for use by NHS healthcare professionals.